XML 66 R43.htm IDEA: XBRL DOCUMENT
v3.20.2

Development, Commercialization and Supply Agreement - Additional Information (Detail) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 28 Months Ended | 37 Months Ended | 59 Months Ended | 68 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | ---
Feb. 29, 2020 USD ($) | Jan. 31, 2020 USD ($) | Sep. 30, 2018 USD ($) | Sep. 30, 2017 USD ($) | Mar. 31, 2016 USD ($) | Feb. 28, 2015 USD ($) | Sep. 30, 2020 USD ($) | Sep. 30, 2019 USD ($) | Sep. 30, 2020 USD ($) Item | Sep. 30, 2019 USD ($) | Dec. 31, 2018 USD ($) | Dec. 31, 2019 USD ($) | Sep. 30, 2020 USD ($) | Dec. 31, 2019 USD ($) | Sep. 30, 2020 USD ($)
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized related to upfront and milestone payments |  |  |  |  |  |  |  |  | $ 5,691,000 | $ 1,131,000 |  |  |  |  |
Licenses revenue |  |  |  |  |  |  | $ 156,499,000 | $ 112,408,000 | 446,809,000 | 286,478,000 |  |  |  |  |
Deferred revenue |  |  |  |  |  |  | 18,905,000 | 19,579,000 | 18,905,000 | 19,579,000 | $ 20,710,000 | $ 20,846,000 | $ 18,905,000 | $ 20,846,000 | $ 18,905,000
Product Revenue, Net |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Licenses revenue |  |  |  |  |  |  | 155,190,000 | $ 112,250,000 | $ 441,118,000 | 285,347,000 |  |  |  |  |
Mochida | In-licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones payment |  | $ 1,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |
Mochida | In-licenses | Research and Development Expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  |  |  |  |  |  | $ 2,700,000 |  |  |  |
Eddingpharm | Out-licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable up-front received |  |  |  |  |  | $ 15,000,000.0 |  |  |  |  |  |  |  |  |
Number of indications of the regulatory milestone events relating to the submission and approval | Item |  |  |  |  |  |  |  |  | 3 |  |  |  |  |  |
Amounts to be received upon achievement of the regulatory milestone events |  |  |  |  |  |  |  |  | $ 33,000,000.0 |  |  |  |  |  |
Sales-based milestone event payment |  |  |  |  |  |  |  |  | 120,000,000.0 |  |  |  |  |  |
Revenue recognized related to upfront and milestone payments |  |  |  |  |  |  |  |  | 2,200,000 | 200,000 |  |  |  |  |
Deferred revenue |  |  |  |  |  |  | 10,800,000 |  | 10,800,000 |  |  | 13,000,000.0 | 10,800,000 | 13,000,000.0 | 10,800,000
Eddingpharm | Out-licenses | Licensing Revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Licenses revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,000,000.0 | 5,200,000
Eddingpharm | Out-licenses | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone |  |  |  |  |  |  |  |  | 153,000,000.0 |  |  |  |  |  |
Amounts to be received upon achievement of the regulatory milestone events |  |  |  |  |  |  |  |  | 15,000,000.0 |  |  |  |  |  |
Sales-based milestone event payment |  |  |  |  |  |  |  |  | 50,000,000.0 |  |  |  |  |  |
Eddingpharm | Out-licenses | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amounts to be received upon achievement of the regulatory milestone events |  |  |  |  |  |  |  |  | 2,000,000.0 |  |  |  |  |  |
Sales-based milestone event payment |  |  |  |  |  |  |  |  | 5,000,000.0 |  |  |  |  |  |
Eddingpharm | Out-licenses | Clinical Trial Application |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable milestone payment |  |  |  |  | $ 1,000,000.0 |  |  |  |  |  |  |  |  |  |
Biologix FZCo | Out-licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition period of non-refundable up-front payment |  |  |  |  | 10 years |  |  |  |  |  |  |  |  |  |
Biologix FZCo | Out-licenses | Product Revenue, Net |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Licenses revenue |  |  |  |  |  |  | 500,000 |  | 500,000 | 300,000 |  |  |  |  |
HLS | Out-licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable up-front received |  |  |  | $ 5,000,000.0 |  |  |  |  |  |  |  |  |  |  |
Non-refundable milestone payment | $ 2,500,000 | $ 3,800,000 | $ 2,500,000 | $ 2,500,000 |  |  |  |  |  |  |  |  |  |  |
Revenue recognized related to upfront and milestone payments |  |  |  |  |  |  |  |  | 3,500,000 | 900,000 |  |  |  |  |
Deferred revenue |  |  |  |  |  |  | $ 7,400,000 |  | 7,400,000 |  |  | 7,100,000 | 7,400,000 | $ 7,100,000 | $ 7,400,000
Non-refundable up-front received period |  |  |  | 6 months |  |  |  |  |  |  |  |  |  |  |
Non-refundable milestone payment received |  |  |  | $ 3,800,000 |  |  |  |  |  |  |  |  |  |  |
HLS | Out-licenses | Licensing Revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Licenses revenue |  |  |  |  |  |  |  |  |  |  |  | $ 2,900,000 | $ 6,400,000 |  |
HLS | Out-licenses | Product Revenue, Net |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Licenses revenue |  |  |  |  |  |  |  |  | $ 8,500,000 | $ 0 |  |  |  |  |
HLS | Out-licenses | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone |  |  |  | $ 50,000,000.0 |  |  |  |  |  |  |  |  |  |  |

X
- Definition Estimated number of days following the end of the quarter before related revenue is recognized. + References No definition available. + Details
Name: | amrn_DeferredRevenueRecognitionPeriod
Namespace Prefix: | amrn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Eligible milestone payment. + References No definition available. + Details
Name: | amrn_EligibleMilestonePayment
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Eligible regulatory milestone event payment. + References No definition available. + Details
Name: | amrn_EligibleRegulatoryMilestoneEventPayment
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Eligible sales based milestone event payment. + References No definition available. + Details
Name: | amrn_EligibleSalesBasedMilestoneEventPayment
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License And Collaboration Agreements [Line Items] + References No definition available. + Details
Name: | amrn_LicenseAndCollaborationAgreementsLineItems
Namespace Prefix: | amrn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Non-refundable and non-creditable upfront payment. + References No definition available. + Details
Name: | amrn_NonRefundableAndNonCreditableUpfrontPayment
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Non refundable upfront payments received. + References No definition available. + Details
Name: | amrn_NonRefundableUpfrontPaymentsReceived
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Non refundable upfront payments received period. + References No definition available. + Details
Name: | amrn_NonRefundableUpfrontPaymentsReceivedPeriod
Namespace Prefix: | amrn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Nonrefundable milestone payment. + References No definition available. + Details
Name: | amrn_NonrefundableMilestonePayment
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Nonrefundable milestone payment received. + References No definition available. + Details
Name: | amrn_NonrefundableMilestonePaymentReceived
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of regulatory milestone events indications. + References No definition available. + Details
Name: | amrn_NumberOfRegulatoryMilestoneEventsIndications
Namespace Prefix: | amrn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment of milestone. + References No definition available. + Details
Name: | amrn_PaymentOfMilestones
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | amrn_BusinessDevelopmentsAxis=amrn_MochidaPharmaceuticalCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=amrn_InLicensesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | amrn_BusinessDevelopmentsAxis=amrn_EddingpharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=amrn_OutLicensesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=amrn_ClinicalTrialApplicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | amrn_BusinessDevelopmentsAxis=amrn_BiologixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | amrn_BusinessDevelopmentsAxis=amrn_HLSTherapeuticsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |